{"schema_version":"secwatch.filing_event.v1","accession":"0001178670-25-000031","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2025-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.096172+00:00","generated_at":"2026-05-25T09:32:28.622186+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Alnylam co-founder Dr. Phillip A. Sharp to retire from board effective May 8, 2025","bullets":["Dr. Sharp informed the board on March 3, 2025; retirement is not due to any disagreement.","He will continue to serve on Alnylam's Scientific Advisory Board after retirement.","Dr. Sharp co-founded Alnylam in 2002 and is a Nobel Prize winner for RNA splicing.","The company issued a press release on March 5, 2025 announcing the transition."],"urls":{"canonical":"https://secwatch.observer/filing/0001178670-25-000031","json":"https://secwatch.observer/filing/0001178670-25-000031.json","markdown":"https://secwatch.observer/filing/0001178670-25-000031.md","text":"https://secwatch.observer/filing/0001178670-25-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000117867025000031/0001178670-25-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000117867025000031/alny-20250303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T09:32:28.622186+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"91f8fe877b","claim":"Phillip A. Sharp retired as Director at ALNYLAM PHARMACEUTICALS, INC..","evidence_excerpt":"On March 3, 2025, Phillip A. Sharp, Ph.D. informed the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”) of his retirement from the Board, effective as of May 8, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000117867025000031/0001178670-25-000031-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}